Other drug agents
MedKoo product information:
leucovorin calcium is an active metabolite of folic acid (also called folinic acid and citrovorum factor), which does not require metabolism by dihydrofolate reductase, the molecular target of folate antagonist-type chemotherapeutic drugs. Leucovorin calcium counteracts the toxic effects of these medications, 'rescuing' the patient while permitting the antitumor activity of the folate antagonist. This agent also potentiates the effects of fluorouracil and its derivatives by stabilizing the binding of the drug's metabolite to its target enzyme, thus prolonging drug activity. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).
Leucovorin Calcium Tablets contain either 5 mg or 25 mg leucovorin as the calcium salt of N-[4-[[(2-amino-5-formyl-1, 4, 5, 6, 7, 8-hexahydro-4-oxo-6-pteridinyl)-methyl]amino]benzoyl]-L-glutamic acid. This is equivalent to 5.40 mg or 27.01 mg of anhydrous leucovorin calcium. In addition each tablet contains the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, lactose monohydrate, magnesium stearate, and microcrystalline cellulose. The 25mg tablet also contains D&C yellow no. 10 and FD&C blue no. 1. Leucovorin is a water soluble form of reduced folate in the folate group; it is useful as an antidote to drugs which act as folic acid antagonists. These tablets are intended for oral administration only.
Leucovorin is a racemic mixture of the
diastereoisomers of the 5-formyl derivative of tetrahydrofolic acid. The
biologically active compound of the mixture is the (-)-L-isomer, known
as Citrovorum factor, or (-)-folinic acid. Leucovorin does not require
reduction by the enzyme dihydrofolate reductase in order to participate
in reactions utilizing folates as a source of "one-carbon" moieties.
Following oral administration, leucovorin is rapidly absorbed and enters
the general body pool of reduced folates. The increase in plasma and
serum folate activity (determined microbiologically with Lactobacillus
casei) seen after oral administration of leucovorin is predominantly due
(Keyword; CAS#; MedKoo code#)
About us | Services | Products | News | Careers | Contact us